AbbVie Q1 earnings: Immunology still a powerhouse as Skyrizi, Rinvoq hit $5B combined
One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025. AbbVie’s overall revenues for the first quarter ...
One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025.
AbbVie’s overall revenues for the first quarter ...
